Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HWH. WillisLFLindsey FitzgeraldHSHarsh Shah

Discussion

Loading...

Member takes

Overview

Analysis uncovers treatment outcomes in younger chronic lymphocytic leukemia patients, indicating first-line BCL2 inhibition may improve therapeutic timelines.

Key Points

  • BCL2i therapy significantly prolongs time to next treatment compared to BTKi in younger CLL patients, suggesting better long-term management options.
  • Observed median follow-up was 32 months for BTKi and 20.7 months for BCL2i, with no significant difference in overall survival reported.
  • Analysis utilized nationwide electronic health record data to evaluate the impact of first-line therapies on treatment outcomes for CLL.
  • Findings highlight the need for tailored treatment strategies considering long-term implications for younger CLL patients.

Cite This Study

Willis et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d564https://doi.org/10.1182/blood-2025-6316
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience2025
  2. 2Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States2025
  3. 3Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China2025
  4. 4Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  5. 5Real-world discontinuation of cBTKi-based treatments in patients with CLL/SLL in the United States2025